Sanofi Consumer Healthcare India Limited has informed the Exchange that Board of Directors at its meeting held on February 25, 2026, recommended Final Dividend of Rs. 75 per equity share.
SANOFICONR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi Consumer Healthcare India's Board, at its meeting on February 25, 2026, approved audited standalone financial results for the quarter and financial year ended December 31, 2025, with a clean (unmodified) auditor's opinion from Kalyaniwalla & Mistry LLP. The company posted FY25 revenue from operations of Rs. 8,784 million (up ~21% YoY from Rs. 7,245 million) and net profit of Rs. 2,401 million (up ~33% YoY from Rs. 1,810 million), with EPS of Rs. 104.27 versus Rs. 78.59. Q4 FY25 revenue jumped to Rs. 2,510 million and net profit to Rs. 665 million, helped by strong 23% domestic growth and a 932% surge in exports on a low base. The Board has recommended a final dividend of Rs. 75 per equity share (face value Rs. 10), subject to shareholder approval at the upcoming AGM; the record/book closure date will be announced later. M/s. Kishore Bhatia & Associates were re-appointed as Cost Auditor for FY26. Separately, the filing notes that Sanofi's global parent structure changed after it sold a 50% controlling stake in Opella to Clayton, Dubilier & Rice, making Opal JVco S.a.r.l the new ultimate parent.
Strong double-digit earnings growth and a substantial final dividend of Rs. 75 per share signal healthy cash generation and a shareholder-friendly payout, which is typically viewed positively by investors. The change in ultimate parent from Sanofi to Opal JVco (a CD&R-controlled entity) is a structural development worth monitoring, though the immediate impact is limited as operations remain unchanged.